ClinicalTrials.Veeva

Menu
M

Monument Health Clinical Research | Meade Street

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Olezarsen
Obicetrapib
Vancomycin
Finerenone
Testosterone
Evolocumab
Apixaban
Milvexian
Olpasiran
ISIS 678354

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 18 total trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo
Locations recently updated

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided hea...

Enrolling
Coronary Artery Disease
Left Ventricular Dysfunction
Device: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®
Device: IABP Intra-aortic balloon pump

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Placebo
Drug: Obicetrapib

Trial sponsors

Amgen logo
Ionis Pharmaceuticals logo
N
AbbVie logo
Abiomed logo
Bayer logo
CSL Behring logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Summit Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems